Summary information

Study title

Methylation Supernegative Colorectal Cancers - a Key to Unlocking the Secrets of the DNA (de)methylation Machinery, 2019

Creator

Not available

Study number / PID

https://doi.org/10.18712/NSD-NSD2710-V1 (DOI)

Data access

Information not available

Series

Not available

Abstract

Cytosine methylation is essential for the proper epigenetic regulation of gene expression and maintenance of genomic integrity. We aim at expanding existing knowledge about the mechanism of the DNA methylation and demethylation machineries by a systematic analysis of a novel and intriguing subgroup of cancers, which have unusually little promoter hypermethylation. These tumors represent a unique opportunity for direct insight into the molecular and cellular (dys)functions of the DNA (de)methylation machinery and will be studied at several levels by a multi-disciplinary team, using state-of-the art technology and bioinformatics. In addition to novel biological insights, the results from this project may be useful in the clinical management of colorectal cancer patients. Recurrent aberrations among the methylation supernegative tumors represent novel biomarkers that can improve the sensitivity of existing DNA methylation based test for early detection of colorectal cancer, and ultimately the survival of this patient group. Finally, we aim at identifying novel prognostic markers that may improve the stratification of colorectal cancer patients. For further information about ”Methylation Supernegative Colorectal Cancers - a Key to Unlocking the Secrets of the DNA (de)methylation Machinery, 2019”, please contact the principal investigator.

Keywords

Not available

Methodology

Data collection period

20/04/2015 - 19/04/2019

Country

Time dimension

Not available

Analysis unit

Individ

Universe

A total of 86 samples have been sequenced in this study (tumor and normal samples from 43 colorectal cancer patients). Samples were selected to be enriched in supernegative tumors (qualified using a panel of 12 existing DNA methylation biomarkers). Thirty-one "regular" colorectal cancer tumors, consisting of a mixture of CIMP+ (n=12) and CIMP-(n=14) tumors of different stages (I to IV) and localization (rectum, righ or left colon), were also included for comparison.

Sampling procedure

Not available

Kind of data

Annet

Data collection mode

Not available

Funding information

Funder

The Research Council of Norway

Access

Publisher

NSD - Norwegian Centre for Research Data

Publication year

2019-06-12T00:00:00

Terms of data access

Not available

Related publications

Not available